6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2023

Commission File Number: 001-37353

SCINAI IMMUNOTHERAPEUTICS LTD.

(Translation of registrant’s name into English)

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

Explanatory Note

On November 20, 2023 Scinai Immunotherapeutics Ltd. (“Scinai”) issued a press release announcing that it regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity. A copy of the press release is furnished herewith as Exhibit 99.1.

This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2

Exhibit 99.1

Scinai ImmunotherapeuticsRegains Compliance with Nasdaq’s Stockholders’ Equity Rule

JERUSALEM, ISRAEL - Nov. 20, 2023 - ScinaiImmunotherapeutics Ltd. (Nasdaq: SCNI) today announced today the receipt of formal notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity.

Scinai is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, and providing end-to-end boutique CDMO services.

Nasdaq indicated that their determination that the Company complies with Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum $2.5 million in stockholders’ equity, is based on the content of the Company’s Form 6-K dated November 13, 2023. Nasdaq also indicated that if the Company does not evidence such compliance in its next periodic report, Nasdaq may provide notification to the Company that it may be subject to delisting, at which time the Company may appeal the determination to a Hearings Panel.

The November 13 plan filed by Scinai, which forms the basis of Nasdaq’s decision to determine that the Company complies with Listing Rule 5550(b)(1), included:

In a related matter and as reported on November 3, 2023, Scinai received a letter regarding non-compliance with an additional Nasdaq listing requirement to maintain a minimum bid price of $1.00 per share. As reported, the letter is only a notification of deficiency and has no immediate effect on the listing or trading of the Company’s American Depository Shares (“ADSs”), and Scinai intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirement.

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units: In-house development of inflammation and immunology (I&I) biological products beginning with an innovative, de-risked, pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs; and a comprehensive CDMO service to help biotech companies bring their products to market efficiently and effectively by leveraging Scinai’s GMP and non-GMP drug development and manufacturing capabilities for pre-clinical and clinical studies. Company website: www.scinai.com.

Company Contact

Joshua Phillipson | +972 8 930 2529 | joshua.phillipson@scinai.com

Forward-Looking Statements

This press release contains forward-lookingstatements within the meaning of the Private Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,”“plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intendedto identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regardingstrategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of managementare forward-looking statements. Examples of such statements include, but are not limited to, compliance with the listing requirementsof the Nasdaq Stock Market. These forward--looking statements reflect management’s current views with respect to certain current and futureevents and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expectedby the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk that that the Companywill not evidence compliance with Nasdaq listing rules regarding minimum stockholders’ equity in its next periodic report and doesnot cure the non-compliance with the minimum bid price requirement of Nasdaq, that the Company will not be successful in becoming an end-to-endprovider of CDMO services at high international standards, that Scinai may not be able to secure additional capital on attractive terms,if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical andclinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European InvestmentBank (EIB) may accelerate the financial facility under its finance contract with Scinai; Scinai’s ability to acquire rights to additionalproduct opportunities; Scinai’s ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatoryapproval of Scinai’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility willnot be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug developmentinvolves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affectingthe Company is contained under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securitiesand Exchange Commission on April 17, 2023. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.